Effect of ligustrazine on diabetic peripheral neuropathy and its influence on the level of serum CRP
10.3760/cma.j.issn.1008-6706.2018.02.027
- VernacularTitle:川芎嗪辅助治疗糖尿病周围神经病变的疗效及对血清C反应蛋白水平的影响
- Author:
Ping WANG
1
Author Information
1. 德州市市立医院内分泌科
- Keywords:
Ligustrazine;
Diabetic neuropathies;
Comparative effectiveness research;
C -reactive protein
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(2):236-240
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of ligustrazine on diabetic peripheral neuropathy ( DPN) and its influence on the level of serum C reactive protein (CRP).Methods 76 patients with DPN were selected as the subjects .According to the random number table method ,the patients were randomly divided into two groups ,38 cases in each group .The control group was given mecobalamin treatment .The study group was treated with ligustrazine on the basis of the control group .The clinical efficacy of the two groups was observed and compared with the Toronto clinical neurological lesion ( TCSS) score and serum CRP level .Results The study group was markedly effective in 20 cases(52.6％),effective in 15 cases(39.5％),ineffective in 3 cases(7.9％).In the control group,the markedly effective in 13 cases (34.2％),effective in 14 cases(36.8％),invalid in 11 cases(28.9％).The clinical efficacy of the study group was significantly better than that of the control group (Z=-6.447,P<0.05).The total effective rate of the study group(92.1％) was higher than 71.1％of the control group,the difference between the two groups was not statistically significant(χ2 =2.706,P>0.05).The TCSS scores of the two groups were significantly higher than before treatment(all P<0.05).After treatment,the TCSS score of the study group [(7.24 ±2.36)points]was significantly lower than(9.08 ±2.94)points of the control group(t=3.009,P<0.05).The serum CRP levels of the two groups were significantly lower than before treatment (all P<0.05),and the serum CRP level of the study group [(2.82 ±0.36)mg/L]was significantly lower than that of the control group [(3.48 ±0.96)mg/L](t=3.968,P<0.05).Conclusion Ligustrazine in the treatment of patients with DPN can significantly improve the degree of neuropathy and reduce the level of serum CRP ,so the clinical efficacy is ideal .
